A 12-week RCT funded by Mitsubishi Corporation Life Sciences has shown that nicotinamide mononucleotide (NMN) intake has significantly improved certain aspects of muscle mobility, especially gait speed and left grip strength – which the company says presents...
Nicotinamide mononucleotide (NMN) intake improves lower limb function and reduces drowsiness in adults agreed 65 and above, according to an RCT funded by Mitsubishi Corporation Life Sciences Ltd.